Gore On The New FDA Commissioner

31 October 1997

Vice President Al Gore has said that the new Food and DrugAdministration Commissioner should be a re-inventor, someone who understands the new science well and knows how to build a regulatory environment that fosters innovation while absolutely protecting public health.

Mr Gore noted that the Administration is wholeheartedly committed to the cause of comprehensive FDA reform, reports Health News Daily. He added that with all the provisions that it has pushed for now included in either the House or the Senate bill, the trick is to ensure that the Congress puts the right pieces in the final "recombinant" bill.

He also voiced Administration concerns that the numerous rule-makings and studies called for in the bill and design of the Prescription Drug User Fee Act will severely strain FDA resources, leading to delays of new drug approvals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight